DURECT Corporation develops medicines based on its epigenetic regulator program. The companys lead product, larsucosterol (DUR-928), is in Phase IIb clinical trial for treating alcohol-associated hepatitis and nonalcoholic steatohepatitis. They also offer ALZET products for research animal studies. Additionally, they market POSIMIR for post-surgical pain relief and Methydur for attention deficit hyperactivity disorder. The company has agreements with Virginia Commonwealth University Intellectual Property Foundation, Indivior UK Ltd., and Innocoll Pharmaceuticals Limited. DURECT was incorporated in 1998 and is headquartered in Cupertino, California.
Indicator | Value |
---|---|
PER | 100.0 |
EV/EBITDA | 100.0 |
Price/Free Cash Flow' | 100.0 |
ROIC | -% |
Net Debt/EBITDA | 100.0 |